Canine parvovirus (CPV) disease is an acute, highly infectious disease threatening the dog-raising industry. So far there are no effective therapeutic strategies to control this disease. Although the canine transferrin receptor (TfR) was identified as a receptor for CPV infection, whether extracellular domain of TfR (called soluble TfR (sTfR)) possesses anti-CPV activities remains elusive. Here, we used the recombinant sTfR prepared from HEK293T cells with codon-optimized gene structure to investigate its anti-CPV activity both in vitro and in vivo. Our results indicated that codon optimization could significantly improve sTfR expression in HEK293T cells. The prepared recombinant sTfR possessed a binding activity to both CPV and CPV VP2 capsid proteins and significantly inhibited CPV infection of cultured feline F81 cells and decreased the mortality of CPV-infected dogs, which indicates that the sTfR has the anti-CPV activity both in vitro and in vivo.
Introduction
Canine parvovirus (CPV) was first identified in 1978 as a pathogen that is responsible for serious gastroenteritis and myocarditis in dogs [1] . Currently, there are mainly three antigenic types of CPV (CPV-2a, CPV-2b, and CPV-2c) that are prevalent in different countries and cause major infectious disease threatening dog-raising industry. CPV is a small nonenveloped, single-stranded DNA virus [2] [3] [4] . The linear single-strand DNA genome, about 5 kb long, contains two open reading frames (ORFs). One ORF encodes two nonstructural proteins (NS1 and NS2), while the other encodes two structural proteins (VP1 and VP2). VP2 (426 amino acid residues) is the main component in CPV capsid which possesses strong antigenic properties. The canine transferrin receptor (TfR) has been identified as a receptor for CPV infection mediated by VP2-TfR interaction [5] [6] [7] .
TfR is a type II membrane glycoprotein expressed on the cell surface as a homodimer linked by two intermolecular disulphide bonds. Each monomer is comprised of extracellular domain, transmembrane domain, and intracellular domain. The extracellular domain includes stem, proteaselike, apical, and helical regions [8] . Two disulphide bonds are located in the stem region. Under normal physiological conditions, TfR is involved in plasma-to-cell iron transport, in which iron-load transferrin (Tf) can specifically bind to TfR at the helical regions of TfR extracellular domains to form TfR-Tf complex and then enters the cell by endocytosis [9] . Meanwhile, CPV can also bind to TfR at the apical region of TfR extracellular domains through CPV VP2 and then infects 2 BioMed Research International host cells by endocytosis [7] . Therefore, both CPV and ironloaded transferrin can bind to TfR; however, their binding sites are different.
The viral receptor plays an important role in virus infection since it determines the species specificity, tissue tropism, and pathogenesis of the virus [10] . The virus infection is mediated by virus-receptor interaction. Blocking virusreceptor interaction is a common strategy for viral disease control [11] [12] [13] . Therefore, many antiviral drugs have been developed based on blocking virus-receptor interaction [14] .
There are many strategies to block the virus-receptor interaction. One of most extensively used strategies in antiviral research and application is antibodies, which can specifically target the surface proteins of the viral particles, such as the spike proteins of enveloped viruses and the capsid proteins of nonenveloped viruses. These proteins on the viral surface are involved in viral attachment and infection to the host cells. Upon binding to viral surface proteins, the antibodies block the virus-receptor interaction and inhibit virus infection. For instance, the specific antibody against S2 domain of SARS spike protein could block SARS infection [15] . However, since the antibodies used to block virus infection mainly are polyclonal antibodies or anti-sera, which likely lead to animal infection caused by other pathogens contaminated in anti-sera.
Another strategy for blocking the virus-receptor interaction is to use the small synthetic compounds obtained either by high-throughput screening of large antiviral compound libraries or by structure-guided rational design based on the structures and the interaction of viral surface proteins and receptors [16, 17] . Although small synthetic compounds may exhibit the potent antiviral activity, they may also cause some side effects.
Using recombinant virus receptor to block the interaction between virus and host cells is another strategy for blocking the virus-receptor interaction [13] . For instance, Deen and colleagues have investigated using soluble form of recombinant CD4 protein to inhibit HIV virus infection [18] , resulting in a significant inhibition of virus infectivity.
Based on the interaction between CPV and TfR, we proposed that canine extracellular domain of TfR, also called soluble TfR (sTfR), might have the anti-CPV activities. To verify our hypothesis, we used the recombinant sTfR prepared in eukaryotic expression system with codon-optimized sTfR gene to test the anti-CPV of sTfR in cultured cells and in dogs. The results showed that the recombinant sTfR possessed significant anti-CPV activity. [19, 20] . pcDNA3.1-CD5 plasmids containing human CD5 signal peptide were constructed as previously described [20] . Ni-NTA-agarose beads (Qiagen, Germany) were used for sTfR purification. Prestained protein marker and Bio-Rad protein assay kit were purchased from Bio-Rad Laboratories. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco BRL Life Technologies.
Materials and Methods

Codon Optimization and sTfR Expression Vector
Construction. The codons for sTfR were optimized using human preferred codons based on Codon Usage Database (Kazusa DNA Research Institute, Japan). The codonoptimized sTfR gene was synthesized by Shanghai Sangon Biological Engineering Technology & Services. NheI and AgeI restriction sites were introduced at 5 terminus and 3 terminus of the sTfR sequence, respectively. The wildtype sTfR gene was amplified from canine liver based on GenBank sequence (NM 001003111) by RT-PCR using a pair of primers: 5 cgcgctagc(NheI)cggctactgt aaacgtgtagaac, 5 ccgaccggt(AgeI)aaactcattgtcaatatcccat. The wild-type and codon-optimized sTfR genes were subcloned into pcDNA3.1A-CD5 vector to construct their eukaryotic secretory expression vectors, pcDNA3.1A-CD5-sTfRw/His and pcDNA3.1A-CD5-sTfRopt/His, respectively.
Transfection and Expression.
The transfections in HEK293T cells were performed using modified calcium phosphate transfection method as previously described [21] .
Recombinant sTfR Protein Purification.
For sTfR purification, the transiently expressed sTfR in HEK293T cell culture medium was absorbed with Ni-NTA agarose beads (0.5 mL Ni-NTA slurry for 15 mL medium) and incubated at 4 ∘ C overnight with shaking to immobilize His-tag fused sTfR. After precipitation, the beads were washed four times with washing buffer (20 mM Tris, 500 mM NaCl, 10 mM imidazole, pH 8.0). Bound sTfR was eluted with elution buffer (20 mM Tris, 500 mM NaCl, 250 mM imidazole, pH 8.0). The eluted sTfR was dialyzed against PBS (pH 8.0) to eliminate BioMed Research International 3 imidazole. The protein concentrations were determined using Bradford method.
SDS-PAGE and Western
Blot. The protein sample was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% (w/v) gels. The separated proteins on the gel were either stained with Coomassie Brilliant Blue or electroblotted onto a nitrocellulose membrane by using semidry electroblotting apparatus (Bio-Rad). Blotted proteins on the membrane were detected using a mouse anti-His-tag monoclonal antibody followed by a goat anti-mouse IgG conjugated with alkaline phosphatase. The blots were developed using BCIP/NBT substrate system (BioRad).
sTfR Binding Assay.
A slightly modified enzyme-linked immunosorbent assay (ELISA), as previously described [22] , was used for detection of sTfR binding activities to VP2 proteins and CPV. Briefly, the 96-well plate was coated with VP2 (1 g/mL) and CPV (1 × 10 5 TCID 50 /mL) diluted with coat buffer (0.1 M sodium carbonate buffer, pH 9.6), respectively, and blocked with 5% (w/v) nonfat milk in PBST. The rabbit anti-VP2 polyclonal antibodies (1 g/mL) were added into the VP2-or CPV-coated wells for antibody blocking test. After washing, the different amounts of sTfR (5, 2.5, 1.25, 0.63, 0.31, and 0.16 g/mL) in PBST were added into the well for sTfR binding to CPV or VP2 protein. The same amount of BSA was used as a negative control. The mouse anti-His-tag antibody (1 : 1000) and goat anti-mouse IgG-AP (1 : 1000) were used for detection of the adsorbed sTfR fused with His-tag. After development with 4-nitrophenyl phosphate solution, the optical density (OD) of each well was measured with a microplate reader at 405 nm. The sTfR binding activity was indicated by OD values.
Antiviral Assay of sTfR In Vitro.
For antiviral assay in vitro, the feline kidney F81 cells were cultured in DMEM complete medium. When cells reached 95% of confluence, the cells were trypsinized and seeded into a 96-well plate at the density of 10 4 cells/well. At the same time, 10 L CPV with the titer of 1 × 10 5 TCID 50 /mL was mixed with 40 L of 0.1 g/ L TfR protein or with 40 L of 0.1 g/ L BSA as a negative control and incubated at room temperature for 30 min. 50 L of the mixture above was added into each cell and incubated in 5% CO 2 at 37 ∘ C for 6 h. The cell medium was replaced with DMEM complete medium containing 10% FBS and antibiotics and continued to be cultured for 36∼48 h. The cell morphology was checked at the different time points during the culture period using light microscopy. When the negative control cells (treated with BSA + CPV-2a) show obviously pathologic changes, the cells were harvested and were subject to repeated freezing/thawing three times. CPV titer for each well was measured by TICD 50 assay. The anti-CPV activity of recombinant sTfR was evaluated by the viral titer reduction in feline F81 cells.
Antiviral Assay of sTfR In Vivo.
To evaluate sTfR antiviral activity in vivo, 24 local mongrel dogs (6-8 weeks old, 3-4 kg, unimmunized and anti-CPV antibody negative, screened by ELISA with the recombinant CPV VP2) were divided into 3 groups. Eight dogs in group 1 were preinjected intravenously with sTfR (20 mg/kg) at 24 h before virus challenge. Then, all dogs in the three groups were challenged with CPV-2a (5 × 10 7 TICD 50 /kg) by oral infection. The dogs in group 2 (8 dogs) were treated with sTfR with 20 mg/kg doses at 24 h after virus challenge. The dogs in group 3 as a negative control were treated with BSA at the same time point. The dogs in group 1 and group 2 were continuously treated with sTfR at 10 mg/kg/day doses. At the 10 days after challenge, the morbidity and mortality rates of infected dogs in all groups were calculated. The antiviral activity of the sTfR in vivo was evaluated by the reductions of dog morbidity and mortality rates.
Amplification of CPV and Virus Titer Determination.
CPV was amplified in F81 cells and the virus titers determined by TCID 50 .
Statistical Analysis.
Data were analyzed with SPSS 18.0, and the statistically significant differences were checked by test.
Results
Construction of sTfR Expression Vector and Its
Secretory Expression in HEK293T Cells. Canine TfR is a glycoprotein. To prepare biologically active sTfR, the eukaryotic cell line, HEK293T cells were used. First the wild-type sTfR gene (encoding amino acid sequence:
) was amplified by RT-PCR and sTfR codons were optimized with human preferred codons. Wild-type and codon-optimized sTfR gene expression vectors (pcDNA3.1A-CD5-sTfRw/His and pcDNA3.1A-CD5-sTfRopt/His) were constructed using pcDNA3.1A-CD5 vector (Figure 1(a) ), in which the sTfR genes were driven by CMV promoter and fused with human CD5 leader sequence at the N-terminus and His-tag at the C-terminus: the former mediates sTfR secretion, and the later facilitates sTfR protein purification.
To prepare recombinant sTfR, the sTfR vectors, either wild-type or codon-optimized, were transfected into HEK293T cells with calcium phosphate transfection method (pcDNA3.1-CD5 empty vector as a negative control). At 48 h posttransfection, the culture medium was harvested and the recombinant sTfR was purified by Ni-NTA agarose and identified by SDS-PAGE (Figure 1(b) ) and Western blot (Figure 1(c) ).
As shown in Figures 1(b) and 1(c), about 90 kDa protein bands were detected either by SDS-PAGE or Western blot (Figure 1(b) , lane 1, and Figure 1(c), lane 1) , a little higher than the calculated sTfR molecular weight (80 kDa), which might be caused by glycosylation. Those results indicated that the recombinant sTfR could be expressed in HEK293T cells and secreted into the culture medium. were added for each well (BSA as a negative control). Other two 96-well plates were also coated with VP2 (1 g/mL) (c) and CPV (1 × 10 −5 TCID 50 /mL) (d) and were added rabbit anti-VP2 polyclonal antibodies at different amount (1, 2, 5, 10 g/mL) for antibody blocking test. Then the TfR (2.5 g/mL) was added for all of the wells except mock control well. The mouse anti-His antibody and goat anti-mouse IgG-AP were used for detection of the bound sTfR fused with His-tag. After development with 4-nitrophenyl phosphate substrate, the optical density (OD) for each well was measured using microplate reader at 405 nm. The sTfR binding activity was indicated by OD values.
Codon Optimization Can Increase sTfR Expression in Eukaryotic Cells.
To evaluate the effect of codon optimization on sTfR expression in eukaryotic cells, we compared the expression levels of wild-type and codon-optimized sTfR genes in HEK293T cells. It can be seen from Figure 2 that the expression level of codon-optimized sTfR gene (3.7 ± 0.21 g/10 6 cells) was 3-fold higher than that of the wildtype gene (1.2 ± 0.12 g/10 6 cells), indicating that codon optimization could significantly increase sTfR expression in eukaryotic cells.
sTfR Can Bind to CPV and CPV VP2.
The VP2 protein has been identified to interact with canine TfR during CPV attachment and infection to the host cells [6] . To investigate whether the recombinant canine sTfR has the ability to bind to CPV and VP2, we used CPV-2a strain and the recombinant VP2 (prepared in our lab) to test sTfR binding activity using ELISA method. Binding kinetics (Figures 3(a) and 3(b) ) showed that sTfR could bind to both VP2 and CPV in a dosedependent manner. This binding process could be blocked by VP2 antibody, and the blocking capability was directly proportional to the dosages of VP2 antibody (Figures 3(c)  and 3(d) ). These results indicate that the recombinant sTfR prepared in this study can bind to CPV and VP2.
sTfR Inhibits CPV Infection to Host Cells.
To identify whether recombinant sTfR has the ability to inhibit CPV infection, CPV-2a strain was incubated with sTfR or BSA (as a negative control) at the ratio of 1 : 500 (1 viral particle versus 500 sTfR molecules) at 37 ∘ C for 1 h. The host cells F81 were then infected with the sTfR-incubated CPV-2a in a 96-well plate. The morphology of F81 cells was examined at different time points after the infection. CPV viral titer was calculated with TCID 50 . Figure 4(a) showed the morphology of the CPV-infected cells at 48 h postinfection. Figure 4(b) showed the CPV titers in F81 cells treated with different dosages of sTfR.
As shown in Figure 4 (a), the cytopathic effect (CPE) of F81 cells treated with CPV/BSA was much more obvious than that of the cells treated with sTfR/CPV at 48 h postinfection. The CPV titer in sTfR/CPV-infected F81 cells (10 3.26 TCID 50 /mL) was significantly reduced compared with that of the CPV/BSA-infected cells (10 6 .67 TCID 50 /mL) or CPV-infected cells (10 6.70 TCID 50 /mL) (Figure 4(b) ). The degree of virus reduction is proportional to the dosages of sTfR. The above results indicate that the recombinant sTfR can significantly inhibit CPV infection to the host cells in vitro.
sTfR Decreases Mortality Rates of CPV-Infected Dogs.
To evaluate sTfR anti-CPV activity in vivo, the dogs were divided into three groups. Group 1 was treated with sTfR before CPV challenge, while group 2 was treated with sTfR after CPV challenge. Group 3, as a negative control group, was treated with BSA before CPV challenge. Ten days postchallenge, the morbidity and mortality rates of CPV-infected dogs in the three groups were calculated ( Figure 5 ). The mortality rates ( Figure 5(b) ) of CPV-infected dogs either pretreated (sTfR + CPV) or post-treated (CPV + sTfR) with sTfR tended to be lower than that of the control (CPV + BSA). Notably, the mortality rates of CPV-infected dogs in pretreated (sTfR + CPV) group decreased more than 2 times compared with the control group. Interestingly, the mortality ( Figure 5(b) ) rates of sTfR-pretreated dogs were lower than that of sTfR-posttreated dogs, suggesting that sTfR shows not only the therapeutic effects, but also preventive effects. Our results preliminarily indicate that sTfR tends to inhibit CPV infection in vivo.
Discussion
In the present study, we investigated whether recombinant sTfR has the ability to block the CPV infection. Our results show that sTfR could significantly inhibit the CPV infection to the host cells in vitro and tended to decrease the mortality of the experimentally CPV-infected dogs in vivo, suggesting that sTfR has the potential protective effect for CPV control, which provides an important clue for further developments of new anti-CPV agent based on sTfR.
To prepare glycosylated and dimeric recombinant TfR, eukaryotic cell line (HEK293T) was used to express the sTfR for its posttranslational glycosylation and proper folding. The cysteine residue-containing (GYC 3 KRVEPKAGC 12 ER) fragment in the stem of TfR extracellular domain remained in sTfR gene construct for sTfR dimerization through two helix domains interaction and two intermolecular disulphide bounds formation. Our data showed that the sTfR prepared in this study could bind to CPV and VP2 with a high affinity, suggesting that the sTfR possesses the biological activity. We previously used E. coli expression system to prepare the recombinant sTfR; the resulting recombinant sTfR was unable to effectively bind to VP2 and CPV probably due to lacking posttranslational modifications, including glycosylation and disulphide formation because bacterial cytoplasm is a reducing condition that is not favorable for disulfide bound formation [23] .
Codon optimization is a common strategy for the increase of recombinant protein expression. Potent signal peptide sequence could allow recombinant protein to be effectively expressed and secreted [21, 24] . By adopting the strategies of codon optimization and human CD5-signalpeptide mediation, the high-level secretory expression was obtained in this study, and the expression level reached more than 3 g/10 6 cells, which lays the foundation for the largescale preparation of recombinant sTfR for further application.
In the present study, we have only analyzed the sTfR antiviral activity to the CPV-2a subtype, without testing CPV2b and CPV-2c subtype. We speculated that the affinity of sTfR to the different subtypes of CPV might be different since the classification of CPV subtypes is based on VP2 gene sequence, and the infection of CPV to host cells is mediated by VP2-TfR interaction. Thus, the sTfR anti-CPV activity may be different against distinct subtypes of CPV. Nonetheless, it would be interesting and important to test the anti-CPV activity of sTfR for other subtypes of CPV in future studies.
Lastly, the interaction between the soluble receptor and its natural ligand should also be considered during the endeavors of developing soluble receptor-based antiviral agents because the recombinant receptor can bind both virus and natural ligand. The recombinant sTfR bind not only to CPV but also to transferrin, a natural ligand. Although the two ligands do not compete with each other to bind to the natural TfR because their binding sites on the extracellular domain of TfR are different [25] , however, whether the recombinant sTfR interferes with the transferrin-TfR complex internalization, or vice versa, remains to be elucidated. Reducing the affinity of recombinant sTfR to the transferrin through gene mutagenesis would help to weaken the side effects.
